Li Shan, Huang Xiu-li, Sui Jing-zhe, Chen Si-yuan, Xie Yan-tong, Deng Yan, Wang Jian, Xie Li, Li Tai-jie, He Yu, Peng Qi-liu, Qin Xue, Zeng Zhi-yu
Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi, China.
Eur J Pediatr. 2014 Feb;173(2):153-61. doi: 10.1007/s00431-013-2220-3. Epub 2013 Dec 10.
The efficacy of probiotics supplementation in children undergoing Helicobacter pylori (H. pylori) eradication therapy remains controversial. This study aimed to meta-analyze whether probiotics supplementation in triple therapy could improve H. pylori eradication rates and reduce therapy-related side effects in children. Electronic databases PubMed and Embase were searched to identify all randomized controlled trials in pediatric patients comparing probiotics supplementation with placebo or no extra intervention in H. pylori eradication therapy. Two authors independently extracted the data. Results were expressed as odds ratios (ORs) and accompanying 95 % confidence intervals (CIs). Stata version 12.0 was used to perform all statistical analyses. Seven studies consisting of 508 pediatric patients were included in our study. The pooled ORs (studies n = 7) of eradication rates by intention-to-treat and per-protocol analysis in the probiotics group versus the control group were 1.96 (95 % CI 1.28-3.02) and 2.25 (95 % CI 1.41-3.57), respectively. The pooled OR (studies n = 5) of incidence of total side effects was 0.32 (95 % CI 0.13-0.79), with significant heterogeneity observed (I (2) = 71.9 %).
Probiotics supplementation in triple therapy for H. pylori infection may have beneficial effects on eradication and therapy-related side effects, particularly diarrhea, in children.
在接受幽门螺杆菌(H. pylori)根除治疗的儿童中补充益生菌的疗效仍存在争议。本研究旨在进行荟萃分析,以确定在三联疗法中补充益生菌是否能提高儿童幽门螺杆菌的根除率并减少与治疗相关的副作用。通过检索电子数据库PubMed和Embase,以识别所有比较在幽门螺杆菌根除治疗中补充益生菌与安慰剂或无额外干预的儿科患者随机对照试验。两位作者独立提取数据。结果以比值比(OR)和伴随的95%置信区间(CI)表示。使用Stata 12.0版本进行所有统计分析。我们的研究纳入了7项研究,共508名儿科患者。益生菌组与对照组在意向性治疗和符合方案分析中的根除率合并OR(研究n = 7)分别为1.96(95% CI 1.28 - 3.02)和2.25(95% CI 1.41 - 3.57)。总副作用发生率的合并OR(研究n = 5)为0.32(95% CI 0.13 - 0.79),观察到显著异质性(I² = 71.9%)。
在幽门螺杆菌感染的三联疗法中补充益生菌可能对儿童的根除效果和与治疗相关的副作用,特别是腹泻,有有益影响。